Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
Elena Fountzilas(European University Cyprus), Dimitrios Bafaloukos(Metropolitan Hospital), Anastasios Boutis(Theageneio General Hospital), Eleni Res(Hospital Agioi Anargyroi), Georgia-Angeliki Koliou(Hellenic Cooperative Oncology Group), Sofia Lampaki(Aristotle University of Thessaloniki), Iliada Bompolaki(Chania General Hospital ”St. George”), Dimitrios Daoussis(University of Patras), Athanasios Laloysis(Hygeia Hospital), George Fountzilas(Aristotle University of Thessaloniki), Marinos Tsiatas(Athens Medical Center), Giannis Mountzios(Henry Dunant Hospital), Dionisiοs Spyratos(Aristotle University of Thessaloniki), Α. Kotsakis(University of Thessaly), Ηλίας Κοττέας(National and Kapodistrian University of Athens), Emmanouil Saloustros(University of Thessaly), Amanda Psyrri(University General Hospital Attikon), Athina Christopoulou(Agios Andreas Hospital), Miltiadis Chrysanthidis(Metropolitan Hospital), George Papaxoinis(St Savas Hospital), Vassilis Georgoulias(University Hospital of Heraklion), Anastasios Vagionas(Technological Educational Institute of Eastern Macedonia and Thrace), Henry Hiep Vo(The University of Texas MD Anderson Cancer Center), Ioannis Binas(Metropolitan Hospital), Anna Koumarianou(National and Kapodistrian University of Athens), Nikolaos Kentepozidis(Hellenic Airforce General Hospital), Helen Gogas(National and Kapodistrian University of Athens), Konstantinos N. Syrigos(National and Kapodistrian University of Athens), Sofia Levva(Interbalkan Medical Center), Helena Linardou(Metropolitan Hospital), Anna Andreadou(Theageneio General Hospital), Adamantia Nikolaidi(Mitera Hospital)
Cited by 39
Related Papers
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488
Clinical trial design in the era of precision medicine
|Genome Medicine|2022|279
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
|Cancer Research|2011|266